Literature DB >> 31590726

Dopamine and the motivation of cognitive control.

Roshan Cools1, Monja Froböse2, Esther Aarts2, Lieke Hofmans3.   

Abstract

The major ascending neuromodulator dopamine has long been implicated in cognitive control. Effects of dopamine-related disorders and the treatment of the cognitive control deficits associated with these disorders are commonly attributed to modulation of the prefrontal cortex. However, many disorders that are accompanied by cognitive control deficits also implicate abnormal dopamine transmission in the striatum, which has been associated more readily with value-based learning, choice, and motivation. We put forward the hypothesis that effects of dopamine on cognitive control reflect, in part, indirect modulation of value-based learning and choice computations that alter the motivation to exert control. This hypothesis is grounded in accumulating evidence from work with experimental animals as well as neurochemical PET, pharmacologic fMRI, and computational modeling work with healthy volunteers and patients with addictive disorders, ADHD, and Parkinson's disease. Consistent with an "inverted-U"-shaped relationship between dopamine and value-based learning, this evidence suggests that dopaminergic drugs might paradoxically increase our drive away from cognitive control in individuals with high baseline levels of dopamine, perhaps by "overdosing" dopamine levels, and thus reducing the value of cognitive control. The hypothesis has implications for the many dopamine-related disorders, which are often accompanied by either apathy or problems with impulse control, and their pharmacotreatment with dopaminergic drugs. For example, the cognitive deficits that are commonly associated with prefrontal cortex dysfunctioning might instead reflect modulation of striatal dopamine and its role in the willingness rather than the ability to exert control.
Copyright © 2019 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Apathy; Cognitive control; Dopamine; Effort; Motivation; Parkinson's disease; Prefrontal cortex; Striatum

Mesh:

Substances:

Year:  2019        PMID: 31590726     DOI: 10.1016/B978-0-12-804281-6.00007-0

Source DB:  PubMed          Journal:  Handb Clin Neurol        ISSN: 0072-9752


  14 in total

1.  Different response to instrumental tests in relation to cognitive demand after dopaminergic stimulation in previously treated patients with Parkinson's disease.

Authors:  Thomas Müller; Ali Harati
Journal:  J Neural Transm (Vienna)       Date:  2020-02-01       Impact factor: 3.575

2.  Novel insights into the effects of levodopa on the up- and downstrokes of writing sequences.

Authors:  Sanne Broeder; Leonardo Boccuni; Britt Vandendoorent; Geert Verheyden; Raf Meesen; Alice Nieuwboer
Journal:  J Neural Transm (Vienna)       Date:  2022-03-31       Impact factor: 3.850

3.  Attentional function and inhibitory control in different substance use disorders.

Authors:  James M Bjork; Lori Keyser-Marcus; Jasmin Vassileva; Tatiana Ramey; David C Houghton; F Gerard Moeller
Journal:  Psychiatry Res       Date:  2022-05-01       Impact factor: 11.225

4.  Single doses of a highly selective inhibitor of phosphodiesterase 1 (lenrispodun) in healthy volunteers: a randomized pharmaco-fMRI clinical trial.

Authors:  Sahib S Khalsa; Teresa A Victor; Rayus Kuplicki; Hung-Wen Yeh; Kimberly E Vanover; Martin P Paulus; Robert E Davis
Journal:  Neuropsychopharmacology       Date:  2022-04-29       Impact factor: 8.294

5.  The Selective Dopamine D2 Blocker Sulpiride Modulates the Relationship Between Agentic Extraversion and Executive Functions.

Authors:  Wiebke Herrmann; Jan Wacker
Journal:  Cogn Affect Behav Neurosci       Date:  2021-04-02       Impact factor: 3.282

6.  Effects of β-Lactolin on Regional Cerebral Blood Flow within the Dorsolateral Prefrontal Cortex during Working Memory Task in Healthy Adults: A Randomized Controlled Trial.

Authors:  Yasuhisa Ano; Masahiro Kita; Keiko Kobayashi; Takashi Koikeda; Ryuta Kawashima
Journal:  J Clin Med       Date:  2021-01-28       Impact factor: 4.241

7.  Biological and Pharmacological Characterization of Ascorbic Acid and Nicotinamide Chitosan Nanoparticles against Insulin-Resistance-Induced Cognitive Defects: A Comparative Study.

Authors:  Hend Abd-Allah; Maha Nasr; Omar A H Ahmed-Farid; Salma A El-Marasy; Rofanda M Bakeer; Rania F Ahmed
Journal:  ACS Omega       Date:  2021-01-25

Review 8.  Modulating brain networks associated with cognitive deficits in Parkinson's disease.

Authors:  Iman Beheshti; Ji Hyun Ko
Journal:  Mol Med       Date:  2021-03-10       Impact factor: 6.354

9.  Levodopa improves handwriting and instrumental tasks in previously treated patients with Parkinson's disease.

Authors:  Thomas Müller; Ali Harati
Journal:  J Neural Transm (Vienna)       Date:  2020-08-19       Impact factor: 3.575

Review 10.  The Biology and Pathobiology of Glutamatergic, Cholinergic, and Dopaminergic Signaling in the Aging Brain.

Authors:  Anna Gasiorowska; Malgorzata Wydrych; Patrycja Drapich; Maciej Zadrozny; Marta Steczkowska; Wiktor Niewiadomski; Grazyna Niewiadomska
Journal:  Front Aging Neurosci       Date:  2021-07-13       Impact factor: 5.750

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.